Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Multicenter, Proof-of-Concept Clinical Trial to Evaluate Efficacy and Safety of BSI-045B mAb Injection in Patients With Moderate to Severe Atopic Dermatitis

NCT05932654 is registered in ClinicalTrials.gov with Biosion, Inc. as lead sponsor.

NCT NCT05932654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05932654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Multicenter, Proof-of-Concept Clinical Trial to Evaluate Efficacy and Safety of BSI-045B mAb Injection in Patients With Moderate to Severe Atopic Dermatitis
Lead sponsor
Biosion, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2023
Completion date
September 18, 2024
Enrollment
22 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis